双膦酸盐类药物在临床应用中的进展

被引:21
作者
黄诚 [1 ]
王诗尧 [2 ]
翁习生
机构
[1] 中国医学科学院北京协和医学院北京协和医院骨科
[2] 中国医学科学院北京协和医学院北京协和医院内分泌科
关键词
D O I
10.13795/j.cnki.sgkz.2016.01.011
中图分类号
R96 [药理学];
学科分类号
100706 [药理学];
摘要
<正>双膦酸盐类药物是一类与含钙晶体具有高度亲和力的人工合成物。1960年初Fleisch等通过机体内存在的焦膦酸化合物对异位钙化有抑制作用得到启发,将在体内易被酶水解的焦膦酸结构中的P-O-P更换成了P-C-P,合成在体内不易被酶水解的稳定化合物。这类药物通过抑制破骨细胞功能,减少破骨细胞数量起到抗骨重吸收作用。目前,在临床使用的双膦酸盐类药物分为三代:第一代双膦酸盐为不含氮
引用
收藏
页码:39 / 42
页数:4
相关论文
共 13 条
[1]
双膦酸盐抗骨肿瘤作用的研究进展 [J].
何贤峰 ;
杨述华 ;
胡勇 .
中国骨肿瘤骨病, 2007, (01) :40-43
[2]
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research [J].
Shane, Elizabeth ;
Burr, David ;
Abrahamsen, Bo ;
Adler, Robert A. ;
Brown, Thomas D. ;
Cheung, Angela M. ;
Cosman, Felicia ;
Curtis, Jeffrey R. ;
Dell, Richard ;
Dempster, David W. ;
Ebeling, Peter R. ;
Einhorn, Thomas A. ;
Genant, Harry K. ;
Geusens, Piet ;
Klaushofer, Klaus ;
Lane, Joseph M. ;
McKiernan, Fergus ;
McKinney, Ross ;
Ng, Alvin ;
Nieves, Jeri ;
O'Keefe, Regis ;
Papapoulos, Socrates ;
Sen Howe, Tet ;
van der Meulen, Marjolein C. H. ;
Weinstein, Robert S. ;
Whyte, Michael P. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (01) :1-23
[3]
Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial [J].
Nishii, Takashi ;
Tamura, Satoru ;
Shiomi, Toshiyuki ;
Yoshikawa, Hideki ;
Sugano, Nobuhiko .
CLINICAL RHEUMATOLOGY, 2013, 32 (12) :1759-1766
[4]
Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer [J].
Andrici, J. ;
Tio, M. ;
Eslick, G. D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (08) :708-716
[5]
Bisphosphonate Use and the Risk of Breast Cancer: A Meta-Analysis of Published Literature [J].
Liu, Yupeng ;
Zhao, Shu ;
Chen, Wangyang ;
Hu, Fulan ;
Zhu, Lin ;
Zhang, Qingyuan ;
Zhao, Yashuang .
CLINICAL BREAST CANCER, 2012, 12 (04) :276-281
[6]
Cyclic Pamidronate Therapy in Children with Osteogenesis Imperfecta [J].
Salehpour, S. ;
Tavakkoli, S. .
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2010, 23 (1-2) :73-80
[7]
Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There an Adjuvant Benefit?.[J].Michael Gnant;Peter Dubsky;Florian Fitzal;Peter Blaha;Sebastian Schoppmann;Günther Steger;Christian Marth;Hellmut Samonigg;Katharina Hüttner;Hannes Fohler;Ernst Ruecklinger;Raimund Jakesz;Richard Greil.Clinical Breast Cancer.2009,
[8]
Excess mortality following hip fracture: a systematic epidemiological review [J].
Abrahamsen, B. ;
van Staa, T. ;
Ariely, R. ;
Olson, M. ;
Cooper, C. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (10) :1633-1650
[9]
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma [J].
Musto, Pellegrino ;
Petrucci, Maria Teresa ;
Bringhen, Sara ;
Guglielmelli, Tommasina ;
Caravita, Tommaso ;
Bongarzoni, Velia ;
Andriani, Alessandro ;
D'Arena, Giovanni ;
Balleari, Enrico ;
Pietrantuono, Giuseppe ;
Boccadoro, Mario ;
Palumbo, Antonio .
CANCER, 2008, 113 (07) :1588-1595
[10]
Exploring the anti-tumour activity of bisphosphonates in early breast cancer [J].
Winter, M. C. ;
Holen, I. ;
Coleman, R. E. .
CANCER TREATMENT REVIEWS, 2008, 34 (05) :453-475